Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

41. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women Schousboe J T, Nyman J A, Kane R L, Ensrud K E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 5-year treatment with alendronate in postmenopausal women with osteopenia. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of postmenopausal women with osteopenia, aged 55 to 75 years, and with a bone mineral density (BMD) T-score between -2.4 and -1.5. Setting The setting

NHS Economic Evaluation Database.2005

42. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Schousboe J T, Ensrud K E, Nyman J (...) A, Melton L J, Kane R L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined universal bone densitometry in women aged 65 years and older combined with alendronate treatment for 5 years for those diagnosed

NHS Economic Evaluation Database.2005

43. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Bisphosphonates (...) (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Bisphosphonates

Health Technology Assessment (HTA) Database.2005

44. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment (...) of postmenopausal osteoporosis Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention

Health Technology Assessment (HTA) Database.2005

46. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. 16093464 2005 08 11 2005 08 16 2016 11 24 1533-4406 353 6 2005 Aug 11 The New England journal of medicine N. Engl. J. Med. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. 555-65 Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy (...) is important. We previously reported results after the first year of this randomized trial comparing the use of full-length parathyroid hormone (1-84) alone, alendronate alone, or both combined. In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1-84). In the data reported here, women who had received parathyroid hormone (1-84) monotherapy (100 microg daily) in year 1 were

NEJM2005

47. Daily and cyclic parathyroid hormone in women receiving alendronate.

Daily and cyclic parathyroid hormone in women receiving alendronate. 16093465 2005 08 11 2005 08 16 2015 11 19 1533-4406 353 6 2005 Aug 11 The New England journal of medicine N. Engl. J. Med. Daily and cyclic parathyroid hormone in women receiving alendronate. 566-75 We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroid hormone therapy could be as effective as daily (...) administration. We randomly assigned 126 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate plus parathyroid hormone (1-34) subcutaneously daily, continued alendronate plus parathyroid hormone (1-34) subcutaneously daily for three 3-month cycles alternating with 3-month periods without parathyroid hormone, or alendronate alone for 15 months. In both parathyroid hormone groups, bone formation indexes rose swiftly. Among the women who were receiving cyclic

NEJM2005

48. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study

Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Kane S, Borisov N N, Brixner D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate (5 or 10 mg/day, or 35 or 70 mg/week) and risedronate (5 mg/day), two commonly prescribed oral bisphosphonates used to treat postmenopausal and glucocorticoid-induced osteoporosis, was examined. Type

NHS Economic Evaluation Database.2004

49. Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Ten years' experience with alendronate for osteoporosis in postmenopausal women. 15028823 2004 03 18 2004 03 23 2016 11 24 1533-4406 350 12 2004 Mar 18 The New England journal of medicine N. Engl. J. Med. Ten years' experience with alendronate for osteoporosis in postmenopausal women. 1189-99 Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated (...) with alendronate for up to 10 years. The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were discharged. Women in the original active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5). In two further extensions (years 6 and 7, and 8 through 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment

NEJM2004

50. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. 14973216 2004 02 19 2004 02 23 2013 11 21 1533-4406 350 8 2004 Feb 19 The New England journal of medicine N. Engl. J. Med. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. 767-76 Osteoporosis is a well-known complication of cardiac transplantation. We conducted a randomized trial comparing alendronate with calcitriol for the prevention of bone loss during (...) the first year after cardiac transplantation. A total of 149 patients were randomly assigned to receive either alendronate (10 mg per day) or calcitriol (0.5 microg per day) a mean (+/-SD) of 21+/-11 days after transplantation. Estimates of bone loss and the incidence of fractures among untreated patients were obtained from a reference group of 27 prospectively recruited patients who received cardiac transplants within the same period as the intervention groups. At one year, the bone mineral density

NEJM2004

51. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) hydrochloride, an agent within the class of drugs called selective oestrogen receptor modulators; and alendronate, a bisphosphonate. In all cases, the prescription drug interventions included calcium and vitamin D supplements. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The base-case study population included women who had not had a hysterectomy and who initiated therapy at age 55 years. They had a normal distribution of age-related baseline

NHS Economic Evaluation Database.2003

52. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. 12759324 2003 05 21 2003 06 13 2016 10 17 0098-7484 289 19 2003 May 21 JAMA JAMA Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. 2525-33 Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of postmenopausal (...) osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates is safe or efficacious or how these agents compare in elderly women is unknown. To determine whether hormone replacement and the bisphosphonate alendronate sodium in combination are efficacious and safe, and how they compare with monotherapy in community-dwelling elderly women. Randomized, double-blind, placebo-controlled, clinical trial. Five hundred seventy-three community-dwelling women age 65 years or older

JAMA2003

53. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. 14500804 2003 09 25 2003 09 29 2016 11 24 1533-4406 349 13 2003 Sep 25 The New England journal of medicine N. Engl. J. Med. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. 1207-15 Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted (...) a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone. A total of 238 postmenopausal women (who were not using bisphosphonates) with low bone mineral density at the hip or spine (a T score of less than -2.5, or a T score of less than -2.0 with an additional risk factor for osteoporosis) were randomly assigned to daily treatment

NEJM2003

54. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. 14500805 2003 09 25 2003 09 29 2016 11 24 1533-4406 349 13 2003 Sep 25 The New England journal of medicine N. Engl. J. Med. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. 1216-26 Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect (...) on bone mineral density. We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular

NEJM2003

55. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial

The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial Chrischilles E A, Dasbach E J, Rubenstein L M, Cook J R, Tabor H K, Black D M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the prevention of osteoporotic fractures. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised postmenopausal women with low bone mineral density (BMD), and

NHS Economic Evaluation Database.2001

56. Alendronate for the treatment of osteoporosis in men.

Alendronate for the treatment of osteoporosis in men. 10979796 2000 09 06 2000 09 06 2015 11 19 0028-4793 343 9 2000 Aug 31 The New England journal of medicine N. Engl. J. Med. Alendronate for the treatment of osteoporosis in men. 604-10 Despite its association with disability, death, and increased medical costs, osteoporosis in men has been relatively neglected as a subject of study. There have been no large, controlled trials of treatment in men. In a two-year double-blind trial, we studied (...) the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis. Approximately one third had low serum free testosterone concentrations at base line; the rest had normal concentrations. Men with other secondary causes of osteoporosis were excluded. All the men received calcium and vitamin D supplements. The main outcome measures were the percent changes in lumbar-spine, hip, and total-body bone mineral density. The men who

NEJM2000

57. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. 9875874 1999 01 12 1999 01 12 2016 11 24 0098-7484 280 24 1998 Dec 23-30 JAMA JAMA Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. 2077-82 Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its (...) effects on fracture risk have not been studied for women without vertebral fractures. To test the hypothesis that 4 years of alendronate would decrease the risk of clinical and vertebral fractures in women who have low bone mineral density (BMD) but no vertebral fractures. Randomized, blinded, placebo-controlled trial. Eleven community-based clinical research centers. Women aged 54 to 81 years with a femoral neck BMD of 0.68 g/cm2 or less (Hologic Inc, Waltham, Mass) but no vertebral fracture; 4432

JAMA1999

58. [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures]

[Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Analisis coste-efectividad de alendronato frente a placebo en la prevencion de fractura de cadera [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Analisis coste-efectividad de alendronato frente a placebo en la prevencion de fractura de cadera [Alendronate cost-effectiveness analysis versus placebo in the prevention of hip fractures] Rodriguez Escolar C (...) , Fidalgo Garcia M L, Rubio Cebrian S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an alendronate-based therapy to prevent the risk of hip fracture in women with osteoporosis. The therapy consisted of 10 mg/day

NHS Economic Evaluation Database.1999

59. Bisphosphonates (alendronate and etidronate) in the management of osteoporosis

Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Best L, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Best L, Milne R. Bisphosphonates (...) (alendronate and etidronate) in the management of osteoporosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives The authors examine whether alendronate and etidronate should be used in the treatment of diagnosed osteoporosis. Authors' conclusions The authors find that the choice of target population is critical to the cost-utility of bisphosphonate treatment. If treatment is targeted towards individuals at high risk of fracture then both alendronate

Health Technology Assessment (HTA) Database.1998

60. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. 9443925 1998 02 19 1998 02 19 2013 11 21 0028-4793 338 8 1998 Feb 19 The New England journal of medicine N. Engl. J. Med. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. 485-92 Estrogen-replacement therapy prevents osteoporosis in postmenopausal women (...) by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear. We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo on bone mineral density in 1174 postmenopausal women under 60 years of age. An additional 435 women who were prepared to receive a combination of estrogen and progestin were randomly assigned to one of the above treatments or open

NEJM1998